IQVIA Holdings Inc. (NYSE:IQV), a global leader in advanced analytics, technology solutions, and clinical research services for the healthcare and life sciences industries, finds itself at a critical ...

Shares of IQVIA Holdings Inc. IQV slipped 1.12% to $199.11 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 ...

While 118 biologics are expected to lose patent protection in the US over the next decade, that $234 billion opportunity for ...

In Part 7 – the final instalment of our inaugural Life Sciences Industry Report – we look more closely at reporting from 2024 ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

S&P 500® EPS growth expected to come in at 13.2%, the highest growth rate in three years Large cap outlier earnings dates ...

Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...

BTIG analyst David Larsen adjusted the firm's stance on IQVIA Holdings (NYSE:IQV), moving from a Buy rating to Neutral. The $36.5 billion market cap company, currently trading near its 52-week low at ...

BTIG analyst David Larsen downgraded Iqvia (IQV) to Neutral from Buy without a price target The firm says clinical research organization ...

Lupin has obtained approval from the USFDA to market a generic form of an HIV medication. The approved drug, equivalent to Symtuza tablets, positions Lupin as the exclusive first-to-file. The tablets ...

Barclays lowered the firm’s price target on Iqvia (IQV) to $235 from $255 and keeps an Overweight rating on the shares. The firm says the life ...